- Home
- YMAB vs ABEO Comparison
YMAB vs ABEO Comparison
Compare YMAB & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YMAB
- ABEO
- Stock Information
- Founded
- YMAB 2015
- ABEO N/A
- Country
- YMAB United States
- ABEO United States
- Employees
- YMAB N/A
- ABEO N/A
- Industry
- YMAB Biotechnology: Pharmaceutical Preparations
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- YMAB Health Care
- ABEO Health Care
- Exchange
- YMAB Nasdaq
- ABEO Nasdaq
- Market Cap
- YMAB 270.5M
- ABEO 253.0M
- IPO Year
- YMAB 2018
- ABEO 1980
- Fundamental
- Price
- YMAB $5.72
- ABEO $5.78
- Analyst Decision
- YMAB Strong Buy
- ABEO Strong Buy
- Analyst Count
- YMAB 10
- ABEO 4
- Target Price
- YMAB $21.10
- ABEO $17.25
- AVG Volume (30 Days)
- YMAB 542.6K
- ABEO 271.9K
- Earning Date
- YMAB 03-04-2025
- ABEO 03-17-2025
- Dividend Yield
- YMAB N/A
- ABEO N/A
- EPS Growth
- YMAB N/A
- ABEO N/A
- EPS
- YMAB N/A
- ABEO N/A
- Revenue
- YMAB $84,553,000.00
- ABEO N/A
- Revenue This Year
- YMAB $6.41
- ABEO N/A
- Revenue Next Year
- YMAB $18.15
- ABEO $15,721.96
- P/E Ratio
- YMAB N/A
- ABEO N/A
- Revenue Growth
- YMAB N/A
- ABEO 147.52
- 52 Week Low
- YMAB $5.60
- ABEO $3.05
- 52 Week High
- YMAB $20.90
- ABEO $9.01
- Technical
- Relative Strength Index (RSI)
- YMAB 35.08
- ABEO 52.03
- Support Level
- YMAB $5.60
- ABEO $5.79
- Resistance Level
- YMAB $6.57
- ABEO $6.16
- Average True Range (ATR)
- YMAB 0.38
- ABEO 0.23
- MACD
- YMAB 0.10
- ABEO 0.02
- Stochastic Oscillator
- YMAB 11.43
- ABEO 50.00
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.